Products - Children and young people | Topic

Showing 24 products

Date | Sort by Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
18 December 2019
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published date:
18 December 2019
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)
Product type:
Guidance
Programme:
Highly specialised technologies guidance
Published date:
27 November 2019
Cannabis-based medicinal products (NG144)
Product type:
Guidance
Programme:
NICE guideline
Published date:
11 November 2019
Fever in under 5s: assessment and initial management (NG143)
Product type:
Guidance
Programme:
NICE guideline
Published date:
7 November 2019
Epilepsies in adults: diagnosis and management update (Please see Epilepsies in children, young people and adults)
Status:
In development
Programme:
NICE guideline
Expected publication date:
7 April 2021
Babies, children and young people's experience of healthcare
Status:
In development
Programme:
NICE guideline
Expected publication date:
7 April 2021
Looked-after children and young people
Status:
In development
Programme:
NICE guideline
Expected publication date:
26 April 2021
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education
Status:
In development
Programme:
NICE guideline
Expected publication date:
12 May 2021
Social, emotional and mental wellbeing in primary and secondary education
Status:
In development
Programme:
NICE guideline
Expected publication date:
28 May 2021
Epilepsies in children, young people and adults
Status:
In development
Programme:
NICE guideline
Expected publication date:
2 June 2021
Self harm: assessment, management and preventing recurrence
Status:
In development
Programme:
NICE guideline
Expected publication date:
26 January 2022
Fenfluramine for treating Dravet syndrome [ID1109]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Selumetinib for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Diabetes (type 1 and type 2) in children and young people: diagnosis and management (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Secukinumab for treating moderate to severe plaque psoriasis in children and young people [ID1669]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Liraglutide for managing obesity in people aged 12 to 17 [ID1630]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Secukinumab for treating active enthesitis-related arthritis and juvenile psoriatic arthritis in people aged 2 to 18 [ID3738]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Omburtamab with radioactive iodine (131I) for treating relapsed neuroblastoma [ID1664]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Children and young people Products

Filter

Product type
1 selected

Guidance programme

Status

New and updated
1 selected

Showing 24 products

Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)

Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)

Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

Cannabis-based medicinal products (NG144)

Fever in under 5s: assessment and initial management (NG143)

Epilepsies in adults: diagnosis and management update (Please see Epilepsies in children, young people and adults)

Babies, children and young people's experience of healthcare

Looked-after children and young people

Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education

Social, emotional and mental wellbeing in primary and secondary education

Epilepsies in children, young people and adults

Self harm: assessment, management and preventing recurrence

Fenfluramine for treating Dravet syndrome [ID1109]

Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]

Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

Selumetinib for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]

Diabetes (type 1 and type 2) in children and young people: diagnosis and management (update)

Secukinumab for treating moderate to severe plaque psoriasis in children and young people [ID1669]

Liraglutide for managing obesity in people aged 12 to 17 [ID1630]

Secukinumab for treating active enthesitis-related arthritis and juvenile psoriatic arthritis in people aged 2 to 18 [ID3738]

Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]

Omburtamab with radioactive iodine (131I) for treating relapsed neuroblastoma [ID1664]

Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]

Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]

Children and young people Products

Filter

Product type1 selected

Guidance programme

Status

New and updated1 selected

Showing 24 products

Product type
1 selected

New and updated
1 selected